May 17, 2022 10:48 AM EDTUpdated May 18, 03:13 PM
R&D
FDA+

Cy­to­ki­net­ic­s' long and wind­ing road to de­vel­op its lead heart drug will face an ad­comm this fall

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Up­dat­ed: To spin off or not to spin off? Gala­pa­gos backpedals on sep­a­ra­tion plans, CEO Paul Stof­fels ex­its ear­ly

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

Dutch biotech gets $146M for late-stage tri­als in three meta­bol­ic dis­or­ders

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

A service from the Financial Times